Xanthine Oxidase Inhibition in Renal Transplant Recipients

• Status: Terminated
• Trial end date: 2018-08-10
• Target enrollment: 0
• Participant gender: All

Summary

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Roberto S Kalil; University of Iowa
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• age 18 years or older

• both genders

• recipients of living donor or deceased-donor kidney transplant with stable renal function

Exclusion Criteria:

• history of gout

• allergy to allopurinol

• use of azathioprine